RxDoctor Payments Data

Mohammad Marashdeh, MD

Interventional Cardiology · Indianapolis, INNPI 1689860819

Payments from drug & device makers

$1,143in general payments, 2019–2025

Across 52 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$233
  • Boston Scientific$146
  • Amgen$133
  • Edwards Lifesciences$132
  • E.r. Squibb & Sons, L.L.C.$86
  • Novartis$75
  • plus $338 from 10 others

What the payments were for

  • Food & beverage$1,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,143 in reported general payments places this provider in the 10th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$92,871
Medicare patients
729
Services billed
1,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis21$531,793
EliquisApixaban355$353,093
EntrestoSacubitril/Valsartan158$194,322
Repatha SureclickEvolocumab57$53,575
XareltoRivaroxaban18$23,415
JardianceEmpagliflozin22$20,868
Praluent PenAlirocumab21$10,905
Atorvastatin Calcium968$7,779
Ezetimibe273$7,183
VascepaIcosapent Ethyl18$7,119
Metoprolol Succinate565$5,663
Ranolazine ErRanolazine23$5,221
Clonidine16$3,062
Carvedilol476$2,685
Rosuvastatin Calcium285$2,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$233$884,887376 claims
NovartisEntresto$75$194,322158 claims
Boehringer IngelheimJardiance$14$20,86822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →